| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 12 Nov 2026 | SCHEDULE 13G |
| 06 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
RICHMOND, VA – November 5, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuin... |
| 04 Nov 2026 |
Form 3: Lloyd Scott MacRae, EVP, Chief Commercial Officer
No securities owned |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
1 October 29, 2026 Perry A. Bernocchi Delivered Via Email Re: Transition Agreement Dear Perry, This letter agreement (this “Agreement”) sets forth the terms of your transition from Executive Vice President, Chief Operating Officer (“COO”... |
| 02 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Richmond, VA – November 2, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, ... |
| 30 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity; |
| 29 Oct 2026 | DEF 14A |
| 19 Oct 2026 | PRE 14A |
| 09 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
RICHMOND, VA – October 9, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is ... |
| 07 Oct 2026 | SCHEDULE 13G |
| 06 Oct 2026 |
Form 4: Gardner-Smith Kenneth, Director
Received 283,554 shares as a grant or award |
| 28 Sep 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
This letter agreement (this “Agreement”) sets forth the terms and conditions of the independent contractor relationship between Edward A. Pesicka (“Pesicka”) and Accendra Health, Inc. (the “Company”). |
| 24 Sep 2026 |
Form 4: Leon Jonathan A, EVP & CFO
Gave up 4,265 shares to cover exercise price or tax ($3.63K) |
| 17 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth |
| 11 Sep 2026 | 144 |
| 17 Aug 2026 |
8-K: Regulation FD Disclosure
RICHMOND, VA – August 17, 2026 – Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. |
| 10 Aug 2026 | 8-A12B |
| 10 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more
This Section 382 Rights Agreement (this “Agreement”), dated as of August 10, 2026, is between Accendra Health, Inc., a Virginia corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as r... |
Loading...